Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Refractory hypertension

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    41 result(s) found for: Refractory hypertension. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2007-003558-27 Sponsor Protocol Number: ASPIRANT Start Date*: 2007-07-30
    Sponsor Name:Olomouc University Hospital and Palacký University School of Medicine, Internal Medicine Dept. I
    Full Title: Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT)
    Medical condition: arterial hypertension resistant to treatment (target blood pressure not reached with a combination of at least three different antihypertensive drugs, one of them being a diuretic)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020783 Hypertension not adequately controlled LLT
    9.1 10020775 Hypertension arterial LLT
    9.1 10038274 Refractory hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-004995-13 Sponsor Protocol Number: 38372 Start Date*: 2012-02-09
    Sponsor Name:Erasmus MC
    Full Title: Endovascular renal sympathetic denervation versus spironolactone for treatment-resistant hypertension: a randomized, multicentric study
    Medical condition: Hypertension
    Disease: Version SOC Term Classification Code Term Level
    14.0 10047065 - Vascular disorders 10020772 Hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-021613-23 Sponsor Protocol Number: Start Date*: 2010-11-24
    Sponsor Name:Cambridge University Hospitals NHS Foundation Trust and University of Cambridge
    Full Title: HYPAZ: An open-label investigation into hypertension induced by pazopanib therapy
    Medical condition: Hypertension induced by pazopanib treatment of various cancer types
    Disease: Version SOC Term Classification Code Term Level
    16.1 10038738 - Respiratory, thoracic and mediastinal disorders 10037400 Pulmonary hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-003442-33 Sponsor Protocol Number: D8480C00038 Start Date*: 2005-11-22
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase II, Randomised, Factorial, Double-blind Study to Investigate the Management of AZD2171-induced Hypertension and Efficacy of AZD2171 at Doses of 30 mg and 45 mg in Patients with Advanced Sol...
    Medical condition: Management of AZD2171-induced hypertension in patients with advanced solid tumours
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-001898-25 Sponsor Protocol Number: DAR-311 Start Date*: 2006-09-21
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: DORADO - Fixed Doses of Darusentan as Compared to Placebo in Resistant Hypertension A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel Group Study to Evaluate the Effica...
    Medical condition: Resistant hypertension
    Disease: Version SOC Term Classification Code Term Level
    8.1 10038274 Refractory hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DK (Completed) DE (Completed) GB (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-001899-20 Sponsor Protocol Number: DAR-311-E Start Date*: 2007-01-16
    Sponsor Name:Gilead Sciences Inc.
    Full Title: DORADO-EX – A Dose-Blinded, Long-Term Safety Extension Study to the Phase 3 DORADO Study (Protocol DAR-311) of Darusentan in Resistant Hypertension A Dose-Blinded, Long-Term Safety Extension Study...
    Medical condition: Resistant hypertension
    Disease: Version SOC Term Classification Code Term Level
    8.1 10038274 Refractory hypertension LLT
    Population Age: Gender: Male, Female
    Trial protocol: GB (Completed) DK (Completed) SE (Prematurely Ended) FR (Completed) DE (Prematurely Ended) IT (Prematurely Ended) ES (Completed)
    Trial results: View results
    EudraCT Number: 2006-003548-42 Sponsor Protocol Number: DAR-312-E Start Date*: 2008-04-15
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: DORADO-AC-EX – A Double-Blind, Active-Controlled, Long-Term Safety Extension Study to the Phase 3 DORADO-AC Study (Protocol DAR-312) of Darusentan in Resistant Hypertension A Double-Blind, Active-...
    Medical condition: Resistant hypertension
    Disease: Version SOC Term Classification Code Term Level
    8.1 10038274 Refractory hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DK (Prematurely Ended) BE (Completed) FR (Completed) DE (Prematurely Ended) ES (Completed) CZ (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-003547-23 Sponsor Protocol Number: DAR-312 Start Date*: 2007-11-15
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: DORADO-AC - Optimized Doses of Darusentan as Compared to an Active Control in Resistant Hypertension A Phase 3 Randomized, Double-Blind, Placebo- and Active-Controlled, Multi-center, Parallel Grou...
    Medical condition: Resistant hypertension
    Disease: Version SOC Term Classification Code Term Level
    8.1 10038274 Refractory hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) GB (Completed) DE (Completed) BE (Completed) DK (Completed) ES (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2019-005008-16 Sponsor Protocol Number: STOPPIT-01 Start Date*: 2021-03-08
    Sponsor Name:University Medical Center Hamburg-Eppendorf
    Full Title: Stop of proton-pump inhibitor treatment in patients with liver cirrhosis – a double-blind, placebo-controlled trial
    Medical condition: Liver cirrhosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10019805 - Hepatobiliary disorders 10019641 Hepatic cirrhosis PT
    20.0 10019805 - Hepatobiliary disorders 10024667 Liver cirrhosis LLT
    20.0 10017947 - Gastrointestinal disorders 10003445 Ascites PT
    20.1 10021881 - Infections and infestations 10051156 Ascites infection LLT
    20.0 10021881 - Infections and infestations 10068547 Bacterascites PT
    20.0 10021881 - Infections and infestations 10068555 Monomicrobial non-neutrocytic bacterascites LLT
    24.1 10021881 - Infections and infestations 10061135 Spontaneous bacterial peritonitis PT
    21.1 10029205 - Nervous system disorders 10019660 Hepatic encephalopathy PT
    20.0 100000004866 10036201 Portal hypertensions HLT
    20.1 10019805 - Hepatobiliary disorders 10036200 Portal hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-002988-10 Sponsor Protocol Number: 1392GJK303 Start Date*: 2012-11-19
    Sponsor Name:Fundación para la investigacion Biomedica
    Full Title: Randomized, double-blind, placebo-controlled trial to compare the effect, three months of follow-on pulse pressure and vascular function of isosorbide mononitrate extended release, associated with ...
    Medical condition: Refractory isolated systolic hypertension
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-004831-47 Sponsor Protocol Number: TWO2-001 Start Date*: 2007-11-30
    Sponsor Name:Linde Gas Therapeutics
    Full Title: Topical Wound Oxygen vs. Compression Therapy in the Management of Refractory, Non-Healing Venous Leg Ulcers; A prospective Randomised Controlled Trial
    Medical condition: Chronic, refarctory, non-healing venous ulcers with a duration of more than two years.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10047260 Venous ulceration LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-001646-18 Sponsor Protocol Number: AMB115811 Start Date*: 2013-04-25
    Sponsor Name:GlaxoSmithKline, S.A.
    Full Title: A randomised, multicentre, double-blind, placebo-controlled study of ambrisentan in subjects with inoperable chronic thromboembolic pulmonary hypertension (CTEPH)
    Medical condition: Subjects with inoperable chronic thromboembolic pulmonary hypertension (CTEPH).
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004855 10068739 Chronic thromboembolic pulmonary hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) AT (Completed) DE (Completed) GB (Prematurely Ended) IT (Prematurely Ended) CZ (Prematurely Ended) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-001642-17 Sponsor Protocol Number: AMB116457 Start Date*: 2013-04-26
    Sponsor Name:GlaxoSmithKline, S.A.
    Full Title: An open-label extension study of the long-term safety, tolerability and efficacy of ambrisentan in subjects with inoperable chronic thromboembolic pulmonary hypertension (CTEPH)
    Medical condition: Subjects with inoperable chronic thromboembolic pulmonary hypertension (CTEPH).
    Disease: Version SOC Term Classification Code Term Level
    15.1 100000004855 10068739 Chronic thromboembolic pulmonary hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) AT (Completed) DE (Completed) GB (Prematurely Ended) CZ (Prematurely Ended) NL (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-004591-35 Sponsor Protocol Number: ADVL1211 Start Date*: 2018-12-14
    Sponsor Name:National Cancer Institute Cancer Therapy Evaluation Program (NCI/CTEP)
    Full Title: A PHASE 1 STUDY OF XL184 (CABOZANTINIB, IND# 116059) IN CHILDREN AND ADOLESCENTS WITH RECURRENT OR REFRACTORY SOLID TUMORS, INCLUDING CNS TUMORS
    Medical condition: Patients with relapsed or refractory solid tumors including CNS tumors and malignant melanoma
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2011-005468-10 Sponsor Protocol Number: C16011 Start Date*: 2012-11-28
    Sponsor Name:Millennium Pharmaceuticals, Inc.
    Full Title: A Phase 3 Randomized, Controlled, Open-label, Multicenter, Safety and Efficacy Study of Dexamethasone Plus MLN9708 or Physician's Choice of Treatment Administered to Patients With Relapsed or Refra...
    Medical condition: Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed) GB (Prematurely Ended) IT (Completed) GR (Completed) ES (Prematurely Ended) DK (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2015-003607-30 Sponsor Protocol Number: AV-951-15-303 Start Date*: 2016-04-21
    Sponsor Name:AVEO PHARMACEUTICALS, INC.
    Full Title: A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma
    Medical condition: Advanced Renal Cell Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10050513 Metastatic renal cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) BE (Completed) CZ (Completed) DK (Completed) ES (Completed) HU (Completed) FR (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-001335-31 Sponsor Protocol Number: virus-specific_CD8_T-cells_001 Start Date*: 2013-11-08
    Sponsor Name:Univerzita Karlova v Praze, 2. lékařská fakulta
    Full Title: Adoptive transfer of CMV specific CD8+ T-cells to treat CMV infection after transplantation
    Medical condition: chronic CMV infection after allogeneic hematopoietic stem cell transplantation in children, refractory to conventional antiviral treatment
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-001306-20 Sponsor Protocol Number: ADVL0815 Start Date*: 2012-03-08
    Sponsor Name:The National Cancer Institute (NCI)
    Full Title: A PHASE I STUDY OF PAZOPANIB AS A SINGLE AGENT FOR CHILDREN WITH RELAPSED OR REFRACTORY SOLID TUMORS, INCLUDING CNS TUMORS
    Medical condition: Refractory solid tumors
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065143 Malignant solid tumour LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2004-004378-10 Sponsor Protocol Number: EORTC 62043 Start Date*: 2005-08-10
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: Multi-center, open-label, non-randomised phase II study to evaluate the activity and tolerability of GW786034 in patients with advanced and/or metastatic soft tissue sarcoma who have relapsed follo...
    Medical condition: Advanced and/or metastatic Soft Tissue Sarcoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) HU (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2012-005745-20 Sponsor Protocol Number: IPR/26 Start Date*: 2013-03-24
    Sponsor Name:MolMed S.p.A.
    Full Title: NGR018: Randomized phase II study of NGR-hTNF plus an anthracycline versus an anthracycline alone in platinum-resistant ovarian cancer
    Medical condition: Advanced or metastatic platinum-resistant ovarian cancer patients
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Jun 13 12:15:22 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA